- Moffitt Cancer Center and Cryoport have entered into a strategic collaboration to integrate Cryoport’s CRYOGENE biorepository services at Moffitt’s Speros campus in Pasco County, Florida.
- The collaboration aims to enhance research in cell and gene therapies, accelerating the discovery of new treatments and supporting Moffitt’s mission to become a global epicentre of innovation in the life sciences.
Moffitt Cancer Center, a leading National Cancer Institute-designated comprehensive cancer centre, has announced a strategic partnership with Cryoport, Inc., a global leader in supply chain solutions for the life sciences sector. The collaboration will see Cryoport’s CRYOGENE business unit provide advanced biorepository services at Moffitt’s Speros campus, located in Pasco County, Florida.
Cryoport’s CRYOGENE is renowned for securely storing biological specimens, which is critical for advancing cell and gene therapy research. As part of the collaboration, CRYOGENE’s cutting-edge biostorage facility will be integrated into the Speros campus development, designed to support emerging technologies and treatments such as cell and gene therapies, immunotherapies, and proton therapies. This biorepository facility will also complement Moffitt’s existing Discovery & Innovation Centre, a 250,000-square-foot facility dedicated to research.
The move is a step towards fulfilling Moffitt Cancer Center’s vision of transforming Speros into a global hub for cell and gene therapy innovation. “Our goal is to make Speros the cell and gene therapy capital of the world,” said Patrick Hwu, M.D., president and CEO of Moffitt Cancer Center. The collaboration will also support Moffitt’s broader aim of accelerating scientific discovery and improving patient care through new treatments.
Cryoport’s support will allow Moffitt to enhance its research capabilities, fostering collaboration across various life sciences disciplines. The biorepository facility will not only provide crucial storage for biological samples but also offer streamlined access for research and clinical activities, making it easier to distribute treatment materials.
Speros is part of a broader master development plan to create a global life sciences campus, which spans multiple phases. Construction on the campus, which will include a proton therapy centre and an outpatient clinic, is already underway and expected to be completed by 2026.